{
    "pmcid": "PMC3548984",
    "var_drug_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "PM/PM (OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) had a higher odds of a disease event relative to EM/EM during 5 years of tamoxifen treatment in Arm A.",
            "Sentence": "CYP2D6 poor metabolizer is associated with increased likelihood of disease event in response to tamoxifen in patients with Disease:Breast Neoplasms as compared to extensive metabolizer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "likelihood of disease event in response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM"
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "PM/IM or PM/EM (OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) showed a trend but not statistically significant association with disease event relative to EM/EM during 5 years of tamoxifen treatment.",
            "Sentence": "CYP2D6 poor metabolizer/intermediate metabolizer or poor metabolizer/extensive metabolizer is not associated with likelihood of disease event in response to tamoxifen in patients with Disease:Breast Neoplasms as compared to extensive metabolizer/extensive metabolizer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "likelihood of disease event in response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "EM/IM or IM/IM (OR=1.23, 95% CI: 0.58\u20132.61, p=0.60) was not associated with disease event relative to EM/EM during 5 years of tamoxifen treatment.",
            "Sentence": "CYP2D6 intermediate metabolizer is not associated with likelihood of disease event in response to tamoxifen in patients with Disease:Breast Neoplasms as compared to extensive metabolizer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "likelihood of disease event in response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen and anastrozole",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "In Arm B (tamoxifen followed by anastrozole), PM/PM (OR=0.60, 95% CI: 0.15\u20132.37, p=0.47) was not associated with disease event relative to EM/EM during 5 years of treatment.",
            "Sentence": "CYP2D6 poor metabolizer is not associated with likelihood of disease event in response to tamoxifen and anastrozole in patients with Disease:Breast Neoplasms as compared to extensive metabolizer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "likelihood of disease event in response to",
            "Multiple drugs And/or": "and",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "In Arm B (tamoxifen followed by anastrozole), PM/PM (OR=0.60, 95% CI: 0.15\u20132.37, p=0.47) was not associated with disease event relative to EM/EM during 5 years of treatment.",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "During years 3-5 on Arm A (continued tamoxifen), PM/PM (OR=2.40, 95% CI: 0.86\u20136.66, p=0.09) showed a trend but not statistically significant association with disease event relative to EM/EM.",
            "Sentence": "CYP2D6 poor metabolizer is not associated with likelihood of disease event in response to tamoxifen in patients with Disease:Breast Neoplasms as compared to extensive metabolizer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "likelihood of disease event in response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM.",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "anastrozole",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "During years 3-5 on Arm B (switched to anastrozole), PM/PM (OR=0.28, 95% CI: 0.03\u20132.30, p=0.23) was not associated with disease event relative to EM/EM.",
            "Sentence": "CYP2D6 poor metabolizer is not associated with likelihood of disease event in response to anastrozole in patients with Disease:Breast Neoplasms as compared to extensive metabolizer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "likelihood of disease event in response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "In contrast, women on Arm B who remained event-free during the first 2 years of tamoxifen, the odds of disease event for PM/PM (OR 0.28, p = 0.23) and the IM/PM or EM/PM group (OR 0.63, p = 0.22) were found to be non-significantly decreased during years 3\u20135 relative to EM/EM.",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
            }
        }
    ],
    "var_fa_ann": [],
    "study_parameters": [
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 166,
            "Study Controls": 287,
            "Characteristics": "ABCSG8 Arm A, tamoxifen 5 years, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.04",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.45,
            "Confidence Interval Start": 1.05,
            "Confidence Interval Stop": 5.73,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 166,
            "Study Controls": 287,
            "Characteristics": "ABCSG8 Arm A, tamoxifen 5 years, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.07",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.67,
            "Confidence Interval Start": 0.95,
            "Confidence Interval Stop": 2.93,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 166,
            "Study Controls": 287,
            "Characteristics": "ABCSG8 Arm A, tamoxifen 5 years, EM/IM or IM/IM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.60",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.23,
            "Confidence Interval Start": 0.58,
            "Confidence Interval Stop": 2.61,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 153,
            "Study Controls": 270,
            "Characteristics": "ABCSG8 Arm B, tamoxifen followed by anastrozole 5 years, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.47",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.6,
            "Confidence Interval Start": 0.15,
            "Confidence Interval Stop": 2.37,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 153,
            "Study Controls": 270,
            "Characteristics": "ABCSG8 Arm B, tamoxifen followed by anastrozole 5 years, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.32",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.76,
            "Confidence Interval Start": 0.43,
            "Confidence Interval Stop": 1.31,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 153,
            "Study Controls": 270,
            "Characteristics": "ABCSG8 Arm B, tamoxifen followed by anastrozole 5 years, EM/IM or IM/IM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.96",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.02,
            "Confidence Interval Start": 0.52,
            "Confidence Interval Stop": 2.01,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 28,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm A, years 1-2 tamoxifen, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.25",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.54,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 41,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm B, years 1-2 tamoxifen, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.46",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.6,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 84,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm A, years 3-5 tamoxifen, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.4,
            "Confidence Interval Start": 0.86,
            "Confidence Interval Stop": 6.66,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 84,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm A, years 3-5 tamoxifen, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.7,
            "Confidence Interval Start": 0.91,
            "Confidence Interval Stop": 3.17,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 61,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm B, years 3-5 anastrozole, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.23",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.28,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 2.3,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 61,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm B, years 3-5 anastrozole, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.22",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.63,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        }
    ],
    "summary": "This pharmacogenomics study investigated the relationship between CYP2D6 metabolism and clinical outcomes in postmenopausal women with estrogen receptor-positive breast cancer enrolled in the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG 8). The trial randomized patients to either 5 years of tamoxifen (Arm A) or 2 years of tamoxifen followed by 3 years of anastrozole (Arm B). CYP2D6 is the rate-limiting enzyme responsible for converting tamoxifen to its active metabolite endoxifen.\n\nUsing a matched case-control design, researchers genotyped CYP2D6 alleles (*3, *4, *6, *10, *41) associated with poor (PM), intermediate (IM), or extensive (EM) metabolism. The common *4 allele was in Hardy-Weinberg equilibrium, addressing quality concerns raised about previous negative studies.\n\nKey findings showed that in Arm A (tamoxifen only), women with PM/PM genotype had significantly higher odds of disease events compared to EM/EM (OR=2.45, p=0.04). Women with one poor allele (PM/IM or PM/EM) showed a trend toward higher event likelihood (OR=1.67, p=0.07). Importantly, no association between CYP2D6 genotype and outcomes was observed in Arm B patients who switched to anastrozole. During years 3-5, PM/PM patients on continued tamoxifen showed increased event risk (OR=2.40, p=0.09), while those who switched to anastrozole did not (OR=0.28, p=0.23).\n\nThe study concludes that the negative effects of reduced CYP2D6 metabolism on tamoxifen efficacy are observed only during tamoxifen administration and are negated by switching to anastrozole, which is not metabolized by CYP2D6.",
    "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
    "pmid": "23213055",
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "PM/PM (OR 2.45, 95% CI: 1.05-5.73; p=0.04) had a higher odds of a disease event relative to EM/EM during 5 years of tamoxifen treatment. *3 is a null allele associated with poor metabolism.",
            "Sentence": "CYP2D6*3 is associated with increased risk of Efficacy:Disease recurrence when treated with tamoxifen in people with Disease:Breast Cancer as compared to EM/EM.",
            "Alleles": "*3",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Disease recurrence",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM"
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3",
                "variant_id": "PA165816578",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "PM/PM (OR 2.45, 95% CI: 1.05-5.73; p=0.04) had a higher odds of a disease event relative to EM/EM during 5 years of tamoxifen treatment. *4 is a null allele associated with poor metabolism. The *4 allele was in Hardy Weinberg Equilibrium (p=0.07).",
            "Sentence": "CYP2D6*4 is associated with increased risk of Efficacy:Disease recurrence when treated with tamoxifen in people with Disease:Breast Cancer as compared to EM/EM.",
            "Alleles": "*4",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Disease recurrence",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM",
                "The common CYP2D6 *4 allele was in Hardy Weinberg Equilibrium.",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*4",
                "variant_id": "PA165816579",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "PM/PM (OR 2.45, 95% CI: 1.05-5.73; p=0.04) had a higher odds of a disease event relative to EM/EM during 5 years of tamoxifen treatment. *6 is a null allele associated with poor metabolism.",
            "Sentence": "CYP2D6*6 is associated with increased risk of Efficacy:Disease recurrence when treated with tamoxifen in people with Disease:Breast Cancer as compared to EM/EM.",
            "Alleles": "*6",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Disease recurrence",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM"
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*6",
                "variant_id": "PA165816581",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58-2.61, p=0.60) did not show significant association with disease events. *10 is a reduced function allele associated with intermediate metabolism.",
            "Sentence": "CYP2D6*10 is not associated with risk of Efficacy:Disease recurrence when treated with tamoxifen in people with Disease:Breast Cancer as compared to EM/EM.",
            "Alleles": "*10",
            "Specialty Population": null,
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Disease recurrence",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*10",
                "variant_id": "PA165816582",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58-2.61, p=0.60) did not show significant association with disease events. *41 is a reduced function allele associated with intermediate metabolism.",
            "Sentence": "CYP2D6*41 is not associated with risk of Efficacy:Disease recurrence when treated with tamoxifen in people with Disease:Breast Cancer as compared to EM/EM.",
            "Alleles": "*41",
            "Specialty Population": null,
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Disease recurrence",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*41",
                "variant_id": "PA165816584",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        }
    ],
    "timestamp": "2025-12-16T11:36:59.902670",
    "prompts_used": {
        "var-drug": "var-drug-v2",
        "var-fa": "improved_v2",
        "study-parameters": "study-parameters-v4",
        "summary": "basic",
        "var-pheno": "var-pheno-v6"
    },
    "term_mappings": {
        "CYP2D6*3": {
            "raw_input": "CYP2D6*3",
            "id": "PA165816578",
            "normalized_term": "CYP2D6*3",
            "url": "https://www.clinpgx.org/haplotype/PA165816578",
            "score": 1.0
        },
        "tamoxifen": {
            "raw_input": "tamoxifen",
            "id": "PA451581",
            "normalized_term": "tamoxifen",
            "url": "https://www.clinpgx.org/chemical/PA451581",
            "score": 1.0
        },
        "CYP2D6*4": {
            "raw_input": "CYP2D6*4",
            "id": "PA165816579",
            "normalized_term": "CYP2D6*4",
            "url": "https://www.clinpgx.org/haplotype/PA165816579",
            "score": 1.0
        },
        "CYP2D6*6": {
            "raw_input": "CYP2D6*6",
            "id": "PA165816581",
            "normalized_term": "CYP2D6*6",
            "url": "https://www.clinpgx.org/haplotype/PA165816581",
            "score": 1.0
        },
        "CYP2D6*10": {
            "raw_input": "CYP2D6*10",
            "id": "PA165816582",
            "normalized_term": "CYP2D6*10",
            "url": "https://www.clinpgx.org/haplotype/PA165816582",
            "score": 1.0
        },
        "CYP2D6*41": {
            "raw_input": "CYP2D6*41",
            "id": "PA165816584",
            "normalized_term": "CYP2D6*41",
            "url": "https://www.clinpgx.org/haplotype/PA165816584",
            "score": 1.0
        },
        "tamoxifen and anastrozole": {
            "raw_input": "tamoxifen and anastrozole",
            "id": "PA448432",
            "normalized_term": "anastrozole",
            "url": "https://www.clinpgx.org/chemical/PA448432",
            "score": 1.0
        },
        "anastrozole": {
            "raw_input": "anastrozole",
            "id": "PA448432",
            "normalized_term": "anastrozole",
            "url": "https://www.clinpgx.org/chemical/PA448432",
            "score": 1.0
        }
    }
}